This meta-analysis indicates that serum VEGF is a clinically significant factor influencing the occurrence, development, and prognosis of multiple myeloma and that the antiangiogenic T-VAD regimen is a better MM treatment than VAD alone. This evidence concerns the gene VEGFA and AL amyloidosis.